Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Bought by ICICI Prudential Asset Management Co Ltd

ICICI Prudential Asset Management Co Ltd raised its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 108.0% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 28,316 shares of the medical research company’s stock after acquiring an additional 14,700 shares during the quarter. Bio-Rad Laboratories accounts for about 1.0% of ICICI Prudential Asset Management Co Ltd’s holdings, making the stock its 28th biggest position. ICICI Prudential Asset Management Co Ltd’s holdings in Bio-Rad Laboratories were worth $9,474,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in BIO. Capital Advisors Ltd. LLC grew its holdings in Bio-Rad Laboratories by 193.8% in the second quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 62 shares during the last quarter. UMB Bank n.a. boosted its holdings in shares of Bio-Rad Laboratories by 140.6% during the third quarter. UMB Bank n.a. now owns 77 shares of the medical research company’s stock worth $26,000 after purchasing an additional 45 shares during the last quarter. EntryPoint Capital LLC purchased a new stake in shares of Bio-Rad Laboratories in the first quarter valued at $51,000. Headlands Technologies LLC purchased a new position in Bio-Rad Laboratories during the second quarter worth about $51,000. Finally, Quarry LP acquired a new stake in Bio-Rad Laboratories in the 2nd quarter worth about $59,000. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Insider Transactions at Bio-Rad Laboratories

In other news, EVP James Barry sold 623 shares of the business’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total transaction of $205,895.27. Following the completion of the sale, the executive vice president now owns 147 shares in the company, valued at $48,582.03. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, COO Andrew J. Last sold 3,000 shares of the firm’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $329.94, for a total transaction of $989,820.00. Following the completion of the sale, the chief operating officer now owns 7,559 shares in the company, valued at approximately $2,494,016.46. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP James Barry sold 623 shares of the stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total transaction of $205,895.27. Following the transaction, the executive vice president now owns 147 shares of the company’s stock, valued at $48,582.03. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 17.50% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Wells Fargo & Company began coverage on Bio-Rad Laboratories in a report on Tuesday, August 27th. They set an “equal weight” rating and a $340.00 price objective for the company. StockNews.com upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Friday, November 1st. Citigroup raised their price target on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Finally, Royal Bank of Canada lifted their price target on Bio-Rad Laboratories from $446.00 to $469.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $391.80.

Bio-Rad Laboratories Trading Down 0.5 %

BIO traded down $1.87 on Wednesday, hitting $362.66. 29,021 shares of the stock traded hands, compared to its average volume of 245,966. Bio-Rad Laboratories, Inc. has a 52 week low of $262.12 and a 52 week high of $387.99. The company has a current ratio of 6.14, a quick ratio of 4.52 and a debt-to-equity ratio of 0.16. The business has a fifty day moving average price of $339.68 and a two-hundred day moving average price of $313.17.

Bio-Rad Laboratories (NYSE:BIO) last announced its earnings results on Wednesday, October 30th. The medical research company reported $2.01 earnings per share for the quarter, beating analysts’ consensus estimates of $1.16 by $0.85. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%. The company had revenue of $649.70 million during the quarter, compared to analyst estimates of $628.18 million. During the same period last year, the company posted $2.33 earnings per share. The firm’s quarterly revenue was up 2.8% compared to the same quarter last year. On average, analysts expect that Bio-Rad Laboratories, Inc. will post 9.93 earnings per share for the current year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.